Strength Training Response of Muscle in GLP-1 Users
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Strength Training, Wait first, then strength training.
- Who it may be relevant to
- Registry conditions: Muscle Mass. Basic parameters: from 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.
Interventions
- Behavioral Strength Training
Participants taking a GLP-1 will undergo a 14-week strength training regimen to determine changes in muscle mass. They will perform a series of resistance training exercises supervised by a personal trainer on 3 days per week. - Other Wait first, then strength training
Participants will be waitlisted and receive the 14-week strength training intervention at the end of the waitlist period. During the waitlist period, participants will get no intervention and then be offered the strength training intervention after the first 14 weeks.
Primary outcome measures
- Muscle mass by d3-creatine dilution [Time frame: Water containing creatine isotope consumed in lab; Urine sample collection on Day 0 and Day 3 at baseline and 14 weeks.]
- Balance testing - Percentage of failed recoveries [Time frame: 2-hour testing session in lab at baseline and 14 weeks.]
Secondary outcome measures (1)
- Muscle function [Time frame: 500-meter timed walk in lab at baseline and 14 weeks]
Eligibility criteria
Inclusion criteria
- Age, 50y+
- Be taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less
- Weight <300 lb
- Pass a health and exercise readiness screening
Exclusion criteria
- Age <50
- Weight >300 lb
- Osteoporosis
- Active metabolic, neoplastic, or cardiovascular disease
- Unable or unwilling to provide consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Prevention
Study locations
United States · 1 center
- Virginia Tech — Blacksburg
Identifiers
NCT: NCT07104539 · 25-707